2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists

A compound of formula IV:

• wherein:
• R is C3–C8 alkyl or (C3–C7 cycloalkyl)C1–C5 alk-di-yl;
• R1 is H, CN, halo, C1–C6 alkyl, C1–C4 haloalkyl, CO2R6, CONR6R6, NR6COR7, NR6R6, OR6, SR6, SOR7, SO2R7 or SO2NR6R6;
• R1a is H, halo or C1–C6 alkyl;
• R2 is H or C1–C6 alkyl;
• R3 and R4 are independently H or C1–C6 alkyl
• R5 is hydrogen, optionally substituted phenyl or optionally substituted heterocycle;
• X is absent or is OCH2 or SCH2;
• X1 is absent or C1–C5 alk-di-yl;
• and
• X2 is absent or is O, S, NH, NHSO2, SO2NH or CH2;
• Y is nitro or amino;
• R6 is independently at each occurrence H, C1–C6 alkyl or phenyl;
• or when two R6 moieties are connected to the same nitrogen atom, then said R6 moieties may combine with the nitrogen to which they are attached to form a pyrollidinyl, piperidinyl or hexamethyleneimino ring;
• and
• R7 is C1–C6 alkyl or phenyl;
• or a salt thereof.